Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention

BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro(®)) therapy affects long-term clinical outcomes of Korean...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Korean J Intern Med
Glavni autori: Sim, Doo Sun, Jeong, Myung Ho, Kim, Weon, Rhew, Jay Young, Yum, Ju Hyup, Kim, Ju Han, Cho, Jeong Gwan, Ahn, Young Keun, Park, Jong Chun, Ahn, Byoung Hee, Kim, Sang Hyung, Kang, Jung Chaee
Format: Artigo
Jezik:Inglês
Izdano: Korean Association of Internal Medicine 2003
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4531627/
https://ncbi.nlm.nih.gov/pubmed/14619381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2003.18.3.129
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items